Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 54.5268
- Book/Share 17.633
- PB 44.752
- Debt/Equity 2.4432
- CurrentRatio 1.3723
- ROIC 0.2572
- MktCap 744001192080.0
- FreeCF/Share 0.5421
- PFCF 1527.096
- PE 63.5225
- Debt/Assets 0.4309
- DivYield 0.0071
- ROE 0.7692
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | LLY | Erste Group | Buy | Hold | -- | -- | June 5, 2025 |
| Downgrade | LLY | HSBC Securities | Buy | Reduce | $1150 | $700 | April 28, 2025 |
| Initiation | LLY | Cantor Fitzgerald | -- | Overweight | -- | $975 | April 22, 2025 |
| Resumed | LLY | BofA Securities | -- | Buy | -- | $997 | Dec. 10, 2024 |
| Initiation | LLY | Bernstein | -- | Outperform | -- | $1100 | Oct. 17, 2024 |
| Resumed | LLY | Citigroup | -- | Buy | -- | $1060 | Sept. 13, 2024 |
News
What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.
Read More
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
Published: June 18, 2025 by: Benzinga
Sentiment: Positive
Scholar Rock SRRK revealed results on Wednesday from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced weight loss.
Read More
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.
Read More
Eli Lilly is making it cheaper and easier to buy high doses of blockbuster weight-loss drug Zepbound
Published: June 17, 2025 by: Fast Company
Sentiment: Positive
Eli Lilly announced on Monday it will soon make the two highest doses of its popular weight-loss drug Zepbound available for self-paying customers on its website.
Read More
JBLU Cutting Back Flights, Solar Stocks Sell, LLY Bid for VERV
Published: June 17, 2025 by: Schwab Network
Sentiment: Negative
Breaking news hits Morning Trade Live with JetBlue (JBLU) cutting back flights after it reported weaker travel demand. Diane King Hall talks about the report and shares how it differs from its airline peers.
Read More
PFE or LLY: Which Is the Better Value Stock Right Now?
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors?
Read More
Want a $1 Million Retirement Portfolio? Invest $100,000 in These 3 Stocks and Wait 10 Years
Published: June 16, 2025 by: 24/7 Wall Street
Sentiment: Positive
Key Points in This Article: Growing a $100,000 investment into a $1 million retirement portfolio in 10 years requires a 25.9% CAGR from high-growth stocks with solid financials.
Read More
Lilly Moves Past 50-Day Average: Should You Buy the Stock Now?
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly and Company LLY has reached a significant support level, making it an attractive option for investors from a technical standpoint. Earlier this week, the stock broke through its 50-day simple moving average (SMA), indicating a potential short-term bullish trend.
Read More
Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY banks on soaring Mounjaro and Zepbound sales to defend its obesity edge amid intensifying competition.
Read More
Drug pricing reform talks with US government lack clarity, industry executives say
Published: June 10, 2025 by: Reuters
Sentiment: Neutral
Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and how reduced prices will be implemented, top executives from Eli Lilly and Merck said at an industry conference on Tuesday.
Read More
Eli Lilly and Company (LLY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Published: June 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly and Company (NYSE:LLY ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 8:00 AM ET Company Participants Lucas E. Montarce - Executive VP & CFO Michael Czapar - Director of Investor Relations Conference Call Participants Unidentified Analyst Get started here.
Read More
Visa, Eli Lilly or Netflix— Which Stock Will Be A Trillion Dollar Company Next?
Published: June 09, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Justin Sullivan / Getty Images Visa Fintech is changing the world and Visa is at the center of it.
Read More
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Read More
Rare Outflow Signals Hit Eli Lilly Shares
Published: June 06, 2025 by: FXEmpire
Sentiment: Neutral
“Buy low, sell high” is a common investing mantra. It's easy to understand, but often hard to execute because emotion gets in the way.
Read More
Lilly's Jake Van Naarden: Lilly's success with GLP-1's allows us to reinvest in oncology
Published: June 05, 2025 by: CNBC Television
Sentiment: Positive
CNBC's Angelica Peebles sits down with Lilly's Head of Oncology, Jake Van Naarden, to discuss what's next in Lilly's oncology pipeline and what Lilly is changing about its clinical trials to make them easier for patients to participate in.
Read More
Welldoc Works with Lilly to Launch a New Personalized Health & Medicine Platform for Those Prescribed Lilly's Incretin Therapies
Published: June 04, 2025 by: Business Wire
Sentiment: Neutral
COLUMBIA, Md.--(BUSINESS WIRE)--Welldoc®, a leader in AI-powered digital health innovation, today announced it will power the newly launched Lilly Health™ Personalized Health & Medicine Platform* (Lilly Health app) with its cardiometabolic digital health platform. The Lilly Health app is designed to support a tailored patient experience for individuals interested in or using Eli Lilly and Company's incretin-based therapies, for the treatment of cardiometabolic conditions, such as obesity, t.
Read More
Top 50 High-Quality Dividend Stocks For June 2025
Published: June 03, 2025 by: Seeking Alpha
Sentiment: Positive
I track 50 high-quality dividend growth stocks to identify opportune investments, updating valuation ratings daily to focus on attractive opportunities. In this turbulent year, my investable universe outperformed SPY and SCHD year-to-date, with a gain of 2.08% compared to 0.56% and -3.36%. This month, 12 stocks had valuation rating changes; 5 were upgrades, including Ferrari, Pool Corporation and Accenture PLC, all with strong expected returns.
Read More
LLY Stock Too Cheap At $750?
Published: June 03, 2025 by: Forbes
Sentiment: Neutral
Question: Why would you pay 81 times earnings for AbbVie stock when you can buy LLY for a similar valuation of 76 times earnings? You wouldn't, especially when you consider three simple facts:
Read More
Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades
Published: June 02, 2025 by: Schwab Network
Sentiment: Positive
"You cannot not believe in science," says Tsvetta Kaleynska. She sees biotech companies outperforming in 2025 despite a slow start to the year.
Read More
Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 46th Annual Global Health Care Conference on June 10, 2025. Lucas Montarce, Lilly executive vice president and chief financial officer, will take part in a fireside chat at 8 a.m.
Read More
Targeting The NaV1.8 Pathway In Pain Management: Eli Lilly And Vertex Lead The Way
Published: June 02, 2025 by: Seeking Alpha
Sentiment: Neutral
Both Vertex and Eli Lilly are entering the non-opioid pain management market, targeting the promising $20B+ opportunity. Vertex's Journavx, targeting NaV1.8, is FDA-approved and shows opioid-level pain relief with fewer side effects, positioning it as a potential new standard of care. Eli Lilly's acquisition of SiteOne Therapeutics and STC-004 brings a once-daily NaV1.8 candidate, with early promising results but limited clinical data so far.
Read More
Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting
Published: June 02, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156) demonstrated an encouraging safety profile and anti-tumor activity across dose and FRα expression levels in women with heavily pre-treated platinum-resistant ovarian cancer, including patients previously treated with mirvetuximab soravtansine. A preliminary overall objective response rate (ORR) of 55% was observed at the potential recommended Phase 2 dose of 4 mg/kg.
Read More
Eli Lilly Rises 1.5% After Key Trading Signal
Published: June 02, 2025 by: Benzinga
Sentiment: Positive
TradePulse Alert Confirms Early Up Move in LLY
Read More
AI picks 3 stocks to buy with your IRS $3,000 tax refund
Published: June 01, 2025 by: Finbold
Sentiment: Positive
With IRS tax refunds set to arrive, averaging around $3,000, many Americans are weighing the best ways to use the extra cash.
Read More
5 Alpha Generating Monsters
Published: May 30, 2025 by: Seeking Alpha
Sentiment: Positive
Any stock can generate alpha, but doing it consistently is rare. These 5 stocks have delivered alpha for 4 out of the last 5 years. Valuation is important, so I screen for it and eliminate overpriced stocks.
Read More
PFE or LLY: Which Is the Better Value Stock Right Now?
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Pfizer (PFE) or Eli Lilly (LLY). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Eli Lilly to Expand Pain Pipeline With $1B SiteOne Buyout Offer
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
LLY inks $1B deal to acquire SiteOne, adding phase II-ready pain drug STC-004 to strengthen its neuroscience pipeline.
Read More
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy?
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.
Read More
Eli Lilly expands neuroscience pipeline with $1B acquisition of SiteOne therapeutics
Published: May 27, 2025 by: Proactive Investors
Sentiment: Positive
Eli Lilly and Co (NYSE:LLY) announced it is acquiring SiteOne Therapeutics, a private biotech firm developing small-molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders, for up to $1 billion. This includes the acquisition of STC-004, a Nav1.8 inhibitor being studied for the treatment of pain.
Read More
Eli Lilly to acquire privately held SiteOne
Published: May 27, 2025 by: Reuters
Sentiment: Positive
Eli Lilly will acquire privately held SiteOne Therapeutics, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain drug.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO Mr. David A. Ricks
- Employees 47000